Zoladex (Goserelin Acetate) Patent Expiration, LOE Window & CMS Spending

Zoladex (Goserelin Acetate) by Tersera Therapeutics: Off-Patent Uncontested (0 AB Generics), 0 AB generics, $716K 2024 CMS Part D & Medicaid spend, and 11 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorTersera Therapeutics
FDA Application & PathwayN019726 (NDA)
Exclusivity / Cliff HorizonOff-Patent Uncontested (0 AB Generics)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity DateNot listed / N/A
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$716K
2024 Medicare Part D Spend$716K
2024 Medicaid Spend$0
Reported Wholesale Price Change (CA SB 17)11 WAC filings (max 43.4% 2-yr change)